Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Some of the adverse events related to the use of regorafenib often limits its use in clinical practice. A study suggests the usefulness of a more flexible dosing, which improves patients’ quality of life without jeopardizing efficacy.

Leave a Reply